|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0014582,
umls-concept:C0017431,
umls-concept:C0026882,
umls-concept:C0079419,
umls-concept:C0086860,
umls-concept:C0144576,
umls-concept:C0205225,
umls-concept:C0220901,
umls-concept:C0332293,
umls-concept:C0681890,
umls-concept:C0812222,
umls-concept:C1516213
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-5-10
|
|
pubmed:abstractText |
TP53 mutations have been associated with resistance to anthracyclines but not to taxanes in breast cancer patients. The MDM2 promoter single nucleotide polymorphism (SNP) T309G increases MDM2 activity and may reduce wild-type p53 protein activity. Here, we explored the predictive and prognostic value of TP53 and CHEK2 mutation status together with MDM2 SNP309 genotype in stage III breast cancer patients receiving paclitaxel or epirubicin monotherapy.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-10655437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-10656431,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-10980197,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-11289122,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-11307150,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-12015983,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-12154352,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-12563309,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-12751373,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-14601643,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-14654539,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-14671306,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-15169927,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-1535557,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-15550242,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-16086636,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-16818855,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-17128209,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-17317675,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-18068131,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-18086778,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-18725978,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-20491880,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-7489358,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-7885406,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-7973635,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-8023157,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-8402885,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-8527388,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-856236,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-8564846,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21556366-9275183
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1932-6203
|
|
pubmed:author |
pubmed-author:AasTuridT,
pubmed-author:AnkerGunG,
pubmed-author:ChrisantharRanjanR,
pubmed-author:FjösneHans EHE,
pubmed-author:KnappskogStianS,
pubmed-author:LøkkevikErikE,
pubmed-author:LønningPer EysteinPE,
pubmed-author:LillehaugJohan RichardJR,
pubmed-author:LundgrenSteinarS,
pubmed-author:MjaalandIngvilI,
pubmed-author:NystedArneA,
pubmed-author:OstenstadBjørnB,
pubmed-author:RisbergTerjeT,
pubmed-author:SchlichtingEllenE,
pubmed-author:SkjønsbergGudbrandG
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
e19249
|
|
pubmed:meshHeading |
pubmed-meshheading:21556366-Antineoplastic Agents,
pubmed-meshheading:21556366-Base Sequence,
pubmed-meshheading:21556366-Breast Neoplasms,
pubmed-meshheading:21556366-Cohort Studies,
pubmed-meshheading:21556366-DNA Primers,
pubmed-meshheading:21556366-Epirubicin,
pubmed-meshheading:21556366-Female,
pubmed-meshheading:21556366-Genes, p53,
pubmed-meshheading:21556366-Genotype,
pubmed-meshheading:21556366-Humans,
pubmed-meshheading:21556366-Mutation,
pubmed-meshheading:21556366-Paclitaxel,
pubmed-meshheading:21556366-Polymorphism, Single Nucleotide,
pubmed-meshheading:21556366-Prognosis,
pubmed-meshheading:21556366-Promoter Regions, Genetic,
pubmed-meshheading:21556366-Proto-Oncogene Proteins c-mdm2,
pubmed-meshheading:21556366-Survival Analysis
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
|
|
pubmed:affiliation |
Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway.
|
